Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ENTO 
Entero Therapeutics, Inc. (ENTO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ENTO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $36
1 Year Target Price $36
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.49% | Avg. Invested days 17 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.45M USD | Price to earnings Ratio - | 1Y Target Price 36 |
Price to earnings Ratio - | 1Y Target Price 36 | ||
Volume (30-day avg) 1 | Beta 0.89 | 52 Weeks Range 0.93 - 5.20 | Updated Date 09/17/2025 |
52 Weeks Range 0.93 - 5.20 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.97 |
Earnings Date
Report Date 2025-08-29 | When - | Estimate - | Actual -0.6802 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -3.32% | Return on Equity (TTM) -24.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 68961853 | Price to Sales(TTM) - |
Enterprise Value 68961853 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.1 | Shares Outstanding 1588580 | Shares Floating 1482030 |
Shares Outstanding 1588580 | Shares Floating 1482030 | ||
Percent Insiders 7.3 | Percent Institutions 2.56 |
Upturn AI SWOT
Entero Therapeutics, Inc.
Company Overview
History and Background
As of my knowledge cut-off date, Entero Therapeutics, Inc. is not a publicly traded company in the US. There is no available information on its founding year, milestones, and evolution as a public entity.
Core Business Areas
Leadership and Structure
Since Entero Therapeutics, Inc. is not a public company with available information on their core businesses, the following is not applicable.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
Without knowing Entero Therapeutics' business area, an industry overview cannot be provided.
Positioning
Without knowing Entero Therapeutics' business area, their market positioning cannot be determined.
Total Addressable Market (TAM)
Without knowing Entero Therapeutics' business area, an estimate of the TAM is unavailable.
Upturn SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
Competitors and Market Share
Key Competitors
Competitive Landscape
A competitive landscape analysis cannot be performed without knowing Entero Therapeutics' business and key competitors.
Growth Trajectory and Initiatives
Historical Growth: Growth trends are unavailable for a private company.
Future Projections: Future projections are unavailable for a private company.
Recent Initiatives: Recent initiatives are unavailable for a private company.
Summary
Because Entero Therapeutics, Inc. appears to be a private company, limited information is available to assess its current state. Therefore, judging its strengths, weaknesses, opportunities, and threats is not possible without further financial and operational data. A more detailed analysis would require access to the company's internal records.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Publicly available databases and search engines.
Disclaimers:
The analysis is based on limited publicly available information. The absence of data may not accurately reflect the company's true status. This is not financial advice. Please consult a professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Entero Therapeutics, Inc.
Exchange NASDAQ | Headquaters Boca Raton, FL, United States | ||
IPO Launch date 2016-10-11 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.enterothera.com |
Full time employees 2 | Website https://www.enterothera.com | ||
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. It develops Adrulipase, an oral, non-systemic, and biologic capsule that is in Phase 2 clinical trials for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP), as well as a recombinant lipase enzyme that enables the digestion of fats and other nutrients in CF and CP patients with EPI. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.